COMBINATION ANTI-CANCER AGENTS

• US 20090221615A1
• Filed: 02/19/2009
• Published: 09/03/2009
• Est. Priority Date: 02/29/2008
• Status: Abandoned Application

• Current Assignee: Spectrum Pharmaceuticals Incorporated (Phillips 66 Company)
• Original Assignee: Spectrum Pharmaceuticals Incorporated (Phillips 66 Company)
• Inventors: Reddy, Guru, Lenaz, Luigi
• Application Number:
  US12/389,318
• Publication Number:
  US 20090221615A1
• Time in Patent Office: Days
• US Class Current: 514/265.100
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/382 having six-membered rings, e.g. thioxanthenes thiothixene A61K31/496
• CPC Class Codes: A61K 31/4985 Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present disclosure relates to methods of treating cancer in mammals by administration of Lucanthone and at least one anti-metabolite. Pharmaceutical compositions and kits comprising Lucanthone and at least one anti-metabolite also are disclosed.

Claims

1. A method of treating cancer in a mammal comprising:

administering Lucanthone to the mammal; and

administering at least one anti-metabolite to the mammal,

wherein said Lucanthone and said at least one anti-metabolite are administered in therapeutically effective amounts.

2. The method of claim 1, wherein said at least one anti-metabolite is folate anti-metabolite.

3. The method of claim 1, wherein said at least one anti-metabolite is Pemetrexed.

4. The method of claim 1, wherein said Lucanthone and said at least one anti-metabolite are administered concurrently.

5. The method of claim 1, wherein said Lucanthone and said at least one anti-metabolite are administered sequentially.

6. The method of claim 5, wherein said Lucanthone and said at least one anti-metabolite are administered within about three hours of each other.

7. The method of claim 5, wherein said Lucanthone and said at least one anti-metabolite are administered within about two hours of each other.

8. The method of claim 5, wherein said Lucanthone and said at least one anti-metabolite are administered within about one hour of each other.

9. The method of claim 1, wherein said cancer is lung cancer.

10. The method of claim 9, wherein said lung cancer is non-small lung carcinoma.

11. The method of claim 1, wherein said therapeutically effective amount of Lucanthone said therapeutically effective amount of at least one anti-metabolite are administered in a single daily dose or divided into more than one daily dose.

12. The method of claim 11, wherein said more than one daily dose is two daily doses.

13. The method of claim 1, wherein said Lucanthone and said at least one anti-metabolite are administered orally.

14. The method of claim 1, wherein said Lucanthone and said at least one anti-metabolite are administered parenterally.

15. The method of claim 1, wherein said Lucanthone and said at least one anti-metabolite are administered in the form of a capsule or tablet.

16. The method of claim 1, wherein said Lucanthone and said at least one anti-metabolite are administered for one or more cycles.

17. The method of claim 16, wherein said one cycle comprises 7 times every 4 days.

18. The method of claim 1, further comprising administering radiation therapy, hormonal therapy or immunotherapy.

19. A pharmaceutical composition comprising therapeutically effective amounts of Lucanthone and at least one anti-metabolite, and a pharmaceutically acceptable carrier.

20. A pharmaceutical kit comprising:

a pharmaceutical composition comprising a therapeutically effective amount of Lucanthone and a pharmaceutically acceptable carrier, and

a pharmaceutical composition comprising a therapeutically effective amount of at least one anti-metabolite and a pharmaceutically acceptable carrier.